Comprehensive Stock Comparison
Compare Mineralys Therapeutics, Inc. (MLYS) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | MLYS | Beta 0.40 vs AGIO's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MLYS | +220.1% vs AGIO's -14.9% |
| Efficiency (ROA) | MLYS | -28.6% ROA vs AGIO's -29.0%, ROIC -107.3% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hypertension and cardiovascular diseases. It generates no revenue currently but aims to monetize its lead candidate lorundrostat — a selective aldosterone synthase inhibitor — through future drug approvals and commercialization. The company's competitive advantage lies in its targeted approach to aldosterone inhibition, which addresses a specific biological pathway in treatment-resistant hypertension.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MLYS leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
AGIO and MLYS operate at a comparable scale, with $45M and $0 in trailing revenue.
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $45M |
| EBITDAEarnings before interest/tax | -$184M | -$470M |
| Net IncomeAfter-tax profit | -$171M | -$401M |
| Free Cash FlowCash after capex | -$171M | -$414M |
| Gross MarginGross profit ÷ Revenue | — | +84.4% |
| Operating MarginEBIT ÷ Revenue | — | -10.6% |
| Net MarginNet income ÷ Revenue | — | -9.0% |
| FCF MarginFCF ÷ Revenue | — | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +54.0% | -111.0% |
Valuation Metrics
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $2.3B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9999.00x |
| Price / BookPrice ÷ Book value/share | 7.43x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MLYS delivers a -29.7% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-31 for AGIO. On the Piotroski fundamental quality scale (0–9), AGIO scores 3/9 vs MLYS's 1/9, reflecting mixed financial health.
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -29.7% | -31.2% |
| ROA (TTM)Return on assets | -28.6% | -29.0% |
| ROICReturn on invested capital | -107.3% | -26.6% |
| ROCEReturn on capital employed | -89.0% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$114M | -$49M |
| Cash & Equiv.Liquid assets | $114M | $89M |
| Total DebtShort + long-term debt | $0 | $40M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in MLYS five years ago would be worth $15,868 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, MLYS leads with a +220.1% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors MLYS at 18.1% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | +11.2% |
| 1-Year ReturnPast 12 months | +220.1% | -14.9% |
| 3-Year ReturnCumulative with dividends | +64.6% | +19.4% |
| 5-Year ReturnCumulative with dividends | +58.7% | -36.4% |
| 10-Year ReturnCumulative with dividends | +58.7% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +18.1% | +6.1% |
Risk & Volatility
MLYS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs MLYS's 61.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.40x | 0.91x |
| 52-Week HighHighest price in past year | $47.65 | $46.00 |
| 52-Week LowLowest price in past year | $8.69 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +61.4% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 948K |
Analyst Outlook
Wall Street rates MLYS as "Buy" and AGIO as "Buy". Consensus price targets imply 77.7% upside for MLYS (target: $52) vs 37.3% for AGIO (target: $42).
| Metric | MLYSMineralys Therape… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $52.00 | $41.50 |
| # AnalystsCovering analysts | 8 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 23 | Feb 26 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | 100 | 167.41 | +67.4% |
| Agios Pharmaceutica… (AGIO) | 100 | 112.59 | +12.6% |
Mineralys Therapeut… (MLYS) returned +59% over 5 years vs Agios Pharmaceutica… (AGIO)'s -36%. A $10,000 investment in MLYS 5 years ago would be worth $15,868 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | $0.00 | $0.00 | — |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | -0.74 | -3.66 | -394.6% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 4Free Cash Flow — 5 Years
Mineralys Therapeutics, Inc. generated $-166M FCF in 2024 (-1043% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
MLYS vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is MLYS or AGIO a better buy right now?
Analysts rate Mineralys Therapeutics, Inc. (MLYS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLYS or AGIO?
Over the past 5 years, Mineralys Therapeutics, Inc. (MLYS) delivered a total return of +58.7%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in MLYS five years ago would be worth approximately $16K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MLYS returned +58.7% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLYS or AGIO?
By beta (market sensitivity over 5 years), Mineralys Therapeutics, Inc. (MLYS) is the lower-risk stock at 0.40β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 128% more volatile than MLYS relative to the S&P 500.
04Which has better profit margins — MLYS or AGIO?
Mineralys Therapeutics, Inc. (MLYS) is the more profitable company, earning 0.0% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLYS leads at 0.0% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MLYS or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MLYS or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Mineralys Therapeutics, Inc. (MLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (MLYS: +58.7%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MLYS and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.